Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma
Drug Resistance Updates · 2026-07 · 87 · 101416
DOI: 10.1016/j.drup.2026.101416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-07. Verfasst von Chi Hin Wong und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong; Shenzhen Research Institute, The Chin…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Exosomes, Pancreatic Neoplasms, RNA, Circular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Grants Council, University Grants Committee, University of Hong Kong, National Natural Science Foundation of China.
Abstract (Originalsprache)
AIMS: Circular RNAs (circRNAs) play important roles in cancer. However, their roles in pancreatic ductal adenocarcinoma (PDAC) progression and therapeutic resistance are underexplored. Here, we investigated the roles and diagnostic potential of circGANAB in PDAC. METHODS: The level of circGANAB was examined in PDAC cell lines, tumor tissues and serum exosomes. A receiver operating characteristic curve was constructed to evaluate the diagnostic performance of circGANAB. The oncogenic roles of circGANAB in PDAC tumor growth, metastasis, and immunotherapy resistance were studied in mouse tumor models. CircRNA-pulldown, followed by RNA sequencing, was performed to identify circGANAB-interacting RNAs. RNA stability assay was performed to investigate the roles of circGANAB in regulating its interacting RNAs. RESULTS: CircGANAB was upregulated in PDAC cell lines, primary tumors and was further upregulated in metastatic tumors, with a positive link to the tumor size and poor prognosis. CircGANAB promoted PDAC cell growth, ferroptosis resistance, and metastasis. Furthermore, circGANAB limited anti-PD-L1 immunotherapy efficacy by inhibiting CD4+ and CD8+ T cell infiltration. Mechanistically, circGANAB directly interacted with tumor suppressive lncRNAs GAS5, lncLDAH3, and TMEM51-AS1 and mRNAs IL-13 and IL-17D, resulting in RNA degradation. Additionally, serum exosomal circGANAB significantly increased with good diagnostic performance as a non-invasive biomarker. Exosome-mediated intratumoral transfer of the oncogenic circGANAB promoted PDAC progression. CONCLUSIONS: The upregulated circGANAB holds promising potential as a novel diagnostic biomarker in PDAC. CircGANAB promotes PDAC tumor growth, metastasis, and immunotherapy resistance through degrading interacting RNAs. These results highlight the significance of circRNAs in the tumor microenvironment and the circRNA-RNA interaction gene regulatory mechanisms underlying oncogenesis and tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong; Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen 518087, China.
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
- School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
- Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong; Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen 518087, China. Electronic addres…
Förderung
- Research Grants Council, University Grants Committee
- University of Hong Kong
- National Natural Science Foundation of China
- Chinese University of Hong Kong
- University Grants Committee
Zitieren
APA
Wong, C. H., Peña-Paladines, J. J., Luo, Z., Ma, C. Y., Lee, Y. L., Lin, Z. X., Xian, Y. F., Hollingsworth, M. A., To, K. F., & Chen, Y. (2026). Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma. Drug Resistance Updates, 87, 101416. https://doi.org/10.1016/j.drup.2026.101416
Vancouver
Wong CH, Peña-Paladines JJ, Luo Z, Ma CY, Lee YL, Lin ZX, et al. Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma. Drug Resistance Updates. 2026;87:101416. doi:10.1016/j.drup.2026.101416
BibTeX
@article{Wong2026,
author = {Wong, Chi Hin and Peña-Paladines, Jessica Jazmin and Luo, Zhiyuan and Ma, Chi Yau and Lee, Yee Lam and Lin, Zhi-Xiu and Xian, Yan-Fang and Hollingsworth, Michael A and To, Ka-Fai and Chen, Yangchao},
title = {Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma},
journal = {Drug Resistance Updates},
year = {2026},
volume = {87},
pages = {101416},
doi = {10.1016/j.drup.2026.101416}
}
EUVIMED